MRNA

MRNA

USD

Moderna Inc. Common Stock

$23.750-0.890 (-3.612%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$24.640

Hoch

$25.150

Tief

$23.710

Volumen

13.75M

Unternehmensfundamentaldaten

Marktkapitalisierung

9.3B

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

11.01M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $23.15Aktuell $23.750Hoch $56.695

Ähnliche Nachrichten

CNBC

November trading, Berkshire's cash hoard, Big Tech's ad revenue and more in Morning Squawk

Here are five key things investors need to know to start the trading day.

Mehr anzeigen
November trading, Berkshire's cash hoard, Big Tech's ad revenue and more in Morning Squawk
Analyst Upgrades

UBS Maintains Buy on Moderna, Lowers Price Target to $40

UBS analyst Eliana Merle maintains Moderna with a Buy and lowers the price target from $70 to $40.

Mehr anzeigen
UBS Maintains Buy on Moderna, Lowers Price Target to $40
AccessWire

Moderna Named a Top Employer by Science for Eleventh Consecutive Year

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2025 Top Employers

Mehr anzeigen
Moderna Named a Top Employer by Science for Eleventh Consecutive Year
Analyst Upgrades

JP Morgan Maintains Underweight on Moderna, Lowers Price Target to $25

JP Morgan analyst Jessica Fye maintains Moderna with a Underweight and lowers the price target from $26 to $25.

Mehr anzeigen
JP Morgan Maintains Underweight on Moderna, Lowers Price Target to $25
Analyst Upgrades

Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven and financial guidance.

Mehr anzeigen
Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection
AccessWire

Moderna to Host Investor Event - Analyst Day

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. today announced that it will host its Investor Event - Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025.The event will include

AccessWire

Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint

Company to discontinue development of mRNA-1647 in congenital CMVCompany will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patientsCompany does not anticipate any impact to its 2025

Bleiben Sie auf dem Laufenden

Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.